Post by Vi

The pressures reshaping biopharma in 2026 are structural — rising scientific complexity, patent cliffs, omnichannel fragmentation, siloed data, and trial economics. Each one is an execution gap, not a technology gap. We pulled the five forces from our latest research: Full report link in the comments 👇